Standout Papers

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-bli... 2014 2026 2018 2022 394
  1. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial (2014)
    Christian Confavreux, Paul O’Connor et al. The Lancet Neurology

Immediate Impact

2 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy
2024 Standout
3 intermediate papers

Works of Deborah Dukovic being referenced

Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study (2260)
2021
Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events
2004

Author Peers

Author Last Decade Papers Cites
Deborah Dukovic 429 137 139 206 198 17 730
Maria Lopez-Bresnahan 410 108 92 119 212 15 674
Juha-Pekka Erälinna 403 197 193 153 161 24 745
Ali Seddighzadeh 368 58 157 141 181 23 728
Orla Tuohy 435 294 100 195 146 8 718
Carola Metzig 313 81 116 61 119 15 693
Ann Bass 504 240 178 193 182 26 718
Nils Koch-Henriksen 530 160 172 116 129 16 694
T. Kinoshita 368 174 60 462 118 26 748
Hiroatsu Hojo 110 16 197 251 97 22 842
I. Koetter 205 278 265 46 44 28 826

All Works

Loading papers...

Rankless by CCL
2026